<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354612</url>
  </required_header>
  <id_info>
    <org_study_id>105CON101</org_study_id>
    <nct_id>NCT02354612</nct_id>
  </id_info>
  <brief_title>Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial</brief_title>
  <official_title>An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <brief_summary>
    <textblock>
      Open-label, continuation study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have&#xD;
      completed a previous TRC105 study and are judged by the investigator to have the potential to&#xD;
      benefit from continued TRC105 therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <other_name>Chimeric Antibody (TRC105) to CD105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>companion therapy selection depends on companion therapy used in the parent study</description>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>companion therapy selection depends on companion therapy used in the parent study</description>
    <other_name>Inlyta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>companion therapy selection depends on companion therapy used in the parent study</description>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>companion therapy selection depends on companion therapy used in the parent study</description>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought&#xD;
             to have potential to derive clinical benefit from continued treatment with TRC105 in&#xD;
             the opinion of the parent study investigator.&#xD;
&#xD;
          -  Willing and able to consent for self to participate in study&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures.&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last&#xD;
             dose of TRC105 in the parent TRC105 study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical event that would make TRC105 therapy inappropriate under the parent&#xD;
             protocol&#xD;
&#xD;
          -  Current treatment in another clinical study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, and in&#xD;
             the judgment of the investigator, would make the subject inappropriate for entry into&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Theuer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tracon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

